Site Search
Displaying results 301 - 310 of 345
Resource | Publications,
Sutezolid belongs to the oxazolidinone class of compounds, which function as protein synthesis inhibitors and were first discovered in the mid-1980s. Linezolid was the first compound of the oxazolidinone class to be approved for treatment of TB. It is most commonly used to treat drug-resistant TB. However, linezolid’s use has been limited by toxicity concerns, particularly haematological effects after periods of treatment over 14 days.
Given the potential of sutezolid, this report explores the patent landscape and considers possible access issues relating to the drug should it become available on the market.
Resource | Publications,
PA-824 belongs to the nitroimidazoles class of compounds and is a derivative of compound CGI-17341 whose anti-TB activity was reported as early as 1993. PA-824 was discovered by Patho- Genesis Corporation, which was subsequently acquired by Chiron Corporation. Novartis AG acquired Chiron Corporation in 2006. PA-824 is a pro-drug, which requires reductive activation of an aromatic nitro group before it becomes effective against TB bacteria.
Resource | Publications,
SQ-109 falls into the class of drugs known as ethylenediamines. The compound was discovered by Sequella Inc in collaboration with the United States National Institutes of Health (NIH). A solid phase method was developed to synthesize more than 63 000 compounds based on the 1,2-ethylenediamine structure of ethambutol. Using a high-throughput screening assay, compounds were identified that affected genes activated during cell membrane repair by the TB bacilli.
Given the potential of SQ109, this report explores the patent landscape and considers possible access issues relating to the drug should it become available on the market.
Resource | Publications,
TB treatment has become more complex, particularly with the emergence of multidrug-resistant (MDR) strains of Mycobacterium tuberculosis. There were approximately 450 000 new cases of multidrug-resistant tuberculosis (MDR-TB) worldwide in 2012.1 MDR-TB is resistant to the two most commonly used TB drugs, isoniazid and rifampicin. It requires extended treatment with second-line drugs that are less effective and have more adverse effects than isoniazid- and rifampicin-based regimens.
Given the emergence of MDR-TB, and the need to shorten treatment duration, new drugs are required. The last of the current anti-TB treatments—rifampicin—was introduced in 1963. Since then, research for new TB treatments had largely come to halt. However, in recent years the pipeline for potential new TB treatments has started to look more promising than it has for the past 50 years.
One compound that is currently in the pipeline and generating interest is AstraZeneca's investigational compound AZD5847. AZD5847 has been identified as a possible new treatment for drug-susceptible TB and/or for MDR-TB.
Resource | Publications,
Delamanid was discovered via a screening programme carried out by Otsuka. The compound belongs to the nitroimidazole class of compounds and is a derivative of compound CGI-17341 whose anti-TB activity was already reported in 1993. Previously known as OPC-67683, delamanid is a mycolic-acid biosynthesis inhibitor found to be free of mutagenicity and to possess highly potent activity against tuberculosis (TB), including multidrug-resistant-tuberculosis (MDR-TB).
Resource | Publications,
The patent landscape in Annex I of this report sets out the key patents and patent applications for bedaquiline, including their geographical patent coverage, as of June 2011. While every effort has been made to obtain comprehensive and accurate information on the status and geographical scope of the patents covering bedaquiline, in many countries patent information is not readily available to the public or not updated on a regular basis. In addition, some patent applications may have been published only after the searches were conducted. As such, there may be other relevant patents which have subsequently been published and which are not included in this landscape. Accordingly, the information provided herein is subject to the above disclaimers.
Resource | Publications,
UNITAID’s Strategy 2013-2016 guides the organization’s response to HIV/AIDS, malaria and TB. In total, these global epidemics kill almost 4 million people every year. Forward looking and flexible, UNITAID collects intelligence on product markets for these diseases in order to inform its investments, which are implemented by the world’s top development organizations.
Resource | Publications,
Nearly 20 years after the WHO declaration of TB as a global public health emergency, major progress has been made towards 2015 global targets set within the context of the Millennium Development Goals (MDGs). Two years ahead of the deadline, the Global Tuberculosis Report 2013 and accompanying supplement Countdown to 2015 assess progress towards the 2015 targets and the top priority actions needed to achieve and/or move beyond them.
This is the eighteenth global report on tuberculosis (TB) published by WHO in a series that started in 1997. It provides a comprehensive and up-to-date assessment of the TB epidemic and progress in implementing and financing TB prevention, care and control at global, regional and country levels using data reported by 197 countries and territories that account for over 99% of the world’s TB cases.
Resource | Fact Sheets,
Systematic screening for active TB is defined as the systematic identification of people with suspected active TB, in a predetermined target group, using tests, examinations or other procedures that can be applied rapidly.
The delay in diagnosing TB and initiating appropriate treatment is often long, especially in groups with poor access to health care. The burden of undetected TB is high in many settings, especially in some risk groups. Many people with active TB do not experience typical TB symptoms in the early stages of the disease. These individuals are unlikely to seek care early, and may not be properly diagnosed when seeking care. This and other barriers along the patient-initiated pathway leads to missed or delayed TB diagnoses.
Resource | Publications,
The purpose of this report is to highlight new developments and key challenges that UNITAID has faced as an organization and donor during 2012. This report will be the last to follow the Board approved key performance indicators (KPIs) set for the UNITAID Strategy 2010-2012. The report summarizes UNITAID’s results measured against the targets for 2012 set by its Executive Board at the beginning of the Strategy cycle for 2010-2012.
The report summarizes UNITAID's results measured against the targets for 2012 set by its Executive Board at the beginning of the Strategy cycle for 2010-2012.